Ligand Pharmaceuticals Incorporated Revenue Growth Rates (LGND), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)
 

LGND's Revenue Growth by Quarter and Year

Ligand Pharmaceuticals Incorporated's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LGND/growth
https://api.csimarket.com/api/v1/companies/LGND/fundamentals
https://api.csimarket.com/api/v1/companies/LGND/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
LGND Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 78.75
2nd Quarter June 63.69
1st Quarter March 51.72
FY 194.16

LGNDs Annual Revenue
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2025 $ 268.09 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2024 $ 167.13 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2023 $ 131.31 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2022 $ 196.25 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2021 $ 277.13 millions




LGND Revenue third quarter 2026 Y/Y Growth Comment
Ligand Pharmaceuticals Incorporated reported fall in Revenue in the third quarter 2026 by -31.8% to $ 78.75 millions, from the same quarter in 2025.
The drop in the third quarter 2026 Ligand Pharmaceuticals Incorporated's Revenue compares unfavorably to the Company's average Revenue rise of 28.77%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 70 other companies have achieved higher Revenue growth. While Ligand Pharmaceuticals Incorporated' s Revenue drop of -31.8% ranks overall at the positon no. 673 in the third quarter 2026.


LGND Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -31.8 %
2nd Quarter June 33.72 %
1st Quarter March 14.1 %
FY   -

Financial Statements
Ligand Pharmaceuticals Incorporated's third quarter 2026 Revenue $ 78.75 millions LGND's Income Statement
Ligand Pharmaceuticals Incorporated's third quarter 2025 Revenue $ 115.46 millions Quarterly LGND's Income Statement


LGND Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 23.64 %
2nd Quarter June 23.14 %
1st Quarter March -13.32 %
FY (Year on Year)   -


Back to LGND Growth rate Comparisons >> Back to LGND Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #71
Healthcare Sector #156
Overall #673

Revenue Y/Y Growth Statistics
High Average Low
221.64 % 28.77 % -72.25 %
(Jun 30 2021)   (Mar 31 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #71
Healthcare Sector #156
Overall #673
Revenue Y/Y Growth Statistics
High Average Low
221.64 % 28.77 % -72.25 %
(Jun 30 2021)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ligand Pharmaceuticals Incorporated's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
142.43 % 12.86 % -59.08 %
(Sep 30 2025)  


LGND's III. Quarter Q/Q Revenue Comment
Ligand Pharmaceuticals Incorporated achieved in the III. Quarter 2026 above company average sequential Revenue jump of 23.64%, to $ 78.75 millions, from $63.69 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Ligand Pharmaceuticals Incorporated's Revenue growth quarter on quarter, overall rank is 474.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #97
Overall #474
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #43
Healthcare Sector #97
Overall #474
Revenue Q/Q Growth Statistics
High Average Low
142.43 % 12.86 % -59.08 %
(Sep 30 2025)  


LGND's III. Quarter Q/Q Revenue Comment
Ligand Pharmaceuticals Incorporated achieved in the III. Quarter 2026 above company average sequential Revenue jump of 23.64%, to $ 78.75 millions, from $63.69 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Ligand Pharmaceuticals Incorporated's Revenue growth quarter on quarter, overall rank is 474.


Ligand Pharmaceuticals Incorporated's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 253.83
Y / Y Revenue Growth (TTM) 1.11 %
Year on Year Revenue Growth Overall Ranking # 419
Seqeuential Revenue Change (TTM) -12.64 %
Seq. Revenue Growth (TTM) Overall Ranking # 2263


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Ligand Pharmaceuticals Incorporated's cumulative twelve months Revenue were $ 254 millions, company would post below average annual Revenue growth of -12.64% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Ligand Pharmaceuticals Incorporated's Revenue growth from the 63.69% growth in Jun 30 2026.

In the Healthcare sector 102 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 380 to 419.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 103
Overall # 419

Revenue TTM Y/Y Growth Statistics
High Average Low
99.11 %
 24.45 %
-53.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 329
S&P 500 # 2263
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Ligand Pharmaceuticals Incorporated's cumulative twelve months Revenue were $ 254 millions, company would post below average annual Revenue growth of -53.95% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Ligand Pharmaceuticals Incorporated's Revenue growth from the 63.69% growth in Jun 30 2026.

In the Healthcare sector 102 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 380 to 419.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 103
Overall # 419

Revenue TTM Y/Y Growth Statistics
High Average Low
99.11 %
24.45 %
-53.95 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 329
S&P 500 # 2263




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LGND's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Sutro Biopharma Inc -6.14%$ -6.138 millions
Zai Lab Limited-6.79%$ -6.794 millions


About Ligand Pharmaceuticals Incorporated Revenue Growth Rates (LGND), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ligand Pharmaceuticals Inc (CIK 886163).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000886163-26-000060
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ligand Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.